Clinical trials: Alopecia
Crohn Disease, Ulcerative Colitis
Expanded Access to Upadacitinib
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility.
- Conditions
- Crohn Disease, Ulcerative Colitis, Idiopathic Arthritis (Including sJIA, pJIA, or JPsA), Atopic Dermatitis
- Trial name
- NCT04159597
- Testing
- Upadacitinib
- Sponsor
- AbbVie
AGA
A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Clinical Study ,the mean change from baseline in vertex target area hair count (TAHC) after treatment for 24 weeks.
- Trial name
- NCT05135468
- Testing
- CU-40102 Spray
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Cutia Therapeutics（Wuxi）Co.,Ltd
Actinic Keratoses
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
This Phase I study is designed to evaluate the systemic exposure and safety of KX2-391 Ointment in adult subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis…
- Trial name
- NCT03575780
- Testing
- KX2-391 Ointment 1%
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Athenex, Inc.
Androgenetic Alopecia
Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV…
- Trial name
- NCT00471510
- Testing
- tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Neosil, Inc.
Androgenetic Alopecia
Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia
This study will be a single center, open-label study of a single concentration of ANR- 001.1. The solution will be applied to the scalp of 14 male subjects by study staff once daily for 7 days.
- Trial name
- NCT05864885
- Testing
- Minoxidil
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Aneira Pharma, Inc.
Hair Thinning
The Effects of an Oral Hair Supplement on Hair Density, Growth, and Microbiome
The purpose of this study is to assess how an oral herbal supplement influences hair density, shine, growth, and microbiome.
- Trial name
- NCT06146166
- Testing
- Oral herbal supplement
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Integrative Skin Science and Research